Dulera Inhaler Approved for Asthma

For people 12 and older

THURSDAY, June 24 (HealthDay News) -- Merck & Co.'s Dulera inhaler has been approved for people 12 and older whose asthma isn't controlled with other medication, the company said Thursday in a news release.

Dulera combines a corticosteroid (mometasone furoate) and a long-acting beta agonist (formoterol fumarate). The latter class of drug increases the risk of asthma-related hospitalization in children and teens, Merck said, so Dulera should only be used by people whose asthma isn't adequately controlled with a different class of drug.

FDA approval of Dulera was based on clinical testing of 12-to-26 weeks among 1,509 people aged 12 and older. The most common adverse reactions included sinus inflammation (sinusitis) and headache.

Dulera isn't a rescue medication and does not replace a fast-acting inhaler to treat symptoms that begin suddenly, Merck said.

More information

The FDA has more about this drug's history.

Scott Roberts

Scott Roberts

Updated on June 24, 2010

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ